First SARMs Protocol: A Conservative Beginner Reference

Selective androgen receptor modulators (SARMs) occupy an unusual position in the preclinical literature: they bind the androgen receptor with tissue selectivity, producing anabolic signalling in muscle and bone while — in published rodent work — sparing prostate and sebaceous tissue to varying degrees. For researchers designing a first protocol, the operative question is not which compound produces the largest effect size, but which produces a characterizable effect with the smallest downstream disruption to the hypothalamic-pituitary-gonadal (HPG) axis. This article outlines a conservative starting framework built around two of the most extensively studied compounds, the dosing logic behind them, and the monitoring and post-cycle steps that a defensible protocol requires.

Choosing a starting compound

The two SARMs with the deepest peer-reviewed dossiers are Ostarine (MK-2866, enobosarm) and RAD-140 (testolone). Both have moved through early-phase human trials — Ostarine in cachexia and sarcopenia populations, RAD-140 in breast cancer and hormone-related indications — which gives researchers access to pharmacokinetic profiles, observed adverse-event patterns, and dose-response ranges that most other compounds in this class do not have.

Ostarine is generally the more conservative first choice. In the 2011 Dalton et al. Phase II trial in cancer-related muscle loss, daily oral doses in the 1–3 mg range produced measurable lean-mass gains over 16 weeks, and the 2013 Dobs et al. follow-up in cachexia patients used comparable ranges with modest suppression of endogenous testosterone and a predictable recovery curve. At research doses above that clinical window, suppression becomes more pronounced, but the compound's half-life (reported around 24 hours) and its lower affinity relative to RAD-140 make it forgiving for a first protocol.

RAD-140 is the stronger anabolic signal per milligram but a correspondingly sharper intervention. In multiple rodent studies, including work by Miller et al. (2011), RAD-140 demonstrated high anabolic-to-androgenic selectivity in muscle tissue with a relatively favourable effect on prostate weight compared to testosterone propionate. However, suppression of luteinizing hormone and endogenous testosterone in animal models is consistent and dose-dependent, and anecdotal human reports — which should be treated as low-quality evidence — describe more noticeable cardiovascular and lipid shifts than Ostarine at equivalent perceived potency.

A defensible first protocol therefore chooses one of the following, not both:

• Ostarine, 20–25 mg once daily, for 12 weeks. The longer duration compensates for the gentler signal and allows clearer attribution of observed changes.
• RAD-140, 10 mg once daily, for 8 weeks. The shorter duration reflects the stronger suppression curve and the preference to exit the cycle before lipid and HPG markers drift further from baseline.

Stacking is not appropriate for a first protocol. Running two compounds simultaneously makes it impossible to attribute any observed outcome — beneficial or adverse — to a single variable, and compounds the suppression burden on the HPG axis.

Dosing consistency and timing

SARMs are orally bioavailable and, for both Ostarine and RAD-140, have half-lives long enough (roughly 16–24 hours in the published data) that a single daily dose produces stable plasma concentrations once steady state is reached. Splitting the dose across the day offers no pharmacokinetic advantage in most reported models and introduces more opportunities for a missed administration.

The practical implication is that researchers should fix a dosing time and hold to it across the full cycle. Morning dosing with a small amount of dietary fat is the conventional choice, primarily because it produces a predictable absorption pattern and aligns the peak plasma window with the active portion of the day for subject observation. Evening dosing is acceptable if held consistent, though some rodent work suggests mild effects on sleep architecture at higher doses, which may confound observation if protocol timing shifts.

Two points deserve emphasis. First, dosing "on training days only" or cycling days on and off within a single cycle has no published rationale for SARMs and disrupts steady-state kinetics without any offsetting benefit. Second, escalating mid-cycle — a pattern sometimes carried over from anabolic steroid frameworks — undermines the attributability of observed effects. The dose chosen at week one should be the dose held through the final week, with the cycle ended on schedule rather than extended.

Suppression: what to expect and how to monitor it

Both Ostarine and RAD-140 suppress endogenous testosterone production in a dose- and duration-dependent manner. The mechanism is straightforward: the compound activates the androgen receptor sufficiently at the hypothalamus and pituitary to reduce GnRH and LH signalling, which in turn reduces testicular testosterone output. In the Dobs et al. Ostarine data, suppression was measurable but partial at clinical doses; at research-range doses used in beginner protocols, suppression should be expected to be more substantial but still recoverable within a standard post-cycle window for most subjects.

The markers that matter for suppression monitoring are total testosterone, free testosterone, LH, FSH, SHBG, and estradiol. A full hormone panel drawn in the week before cycle initiation establishes an individualized baseline. A mid-cycle draw — week 4 for an 8-week RAD-140 protocol, week 6 for a 12-week Ostarine protocol — confirms the expected suppression pattern and flags unusual responses. A post-PCT draw, taken approximately four weeks after the final PCT dose, confirms recovery to within the baseline range.

Beyond the HPG panel, a minimum responsible marker set includes:

• Lipid panel (total cholesterol, LDL, HDL, triglycerides). Both compounds have been reported to shift HDL downward in preliminary data; this is typically transient but should be tracked.
• Liver enzymes (ALT, AST, GGT). Oral non-steroidal AR modulators have shown elevated enzyme patterns in a minority of reports; persistent elevation is a stop condition.
• Complete blood count and basic metabolic panel as a general-health floor.

These three panels, taken at baseline, mid-cycle, and post-PCT, give a research protocol a defensible monitoring spine. Protocols that skip blood work cannot meaningfully distinguish an expected physiological response from an adverse one.

HCG during the cycle: optional, and only for longer runs

Human chorionic gonadotropin (HCG) mimics LH at the testicular level, maintaining intratesticular testosterone and testicular volume during a cycle in which pituitary LH output is suppressed. In traditional anabolic steroid protocols, HCG is run during the cycle to prevent the testicular atrophy that otherwise accompanies prolonged suppression. For SARMs — and particularly for a first SARMs cycle — the calculus is different.

For an 8-week RAD-140 protocol, HCG is generally unnecessary. Suppression is present but the duration is short enough that testicular function typically recovers during standard PCT without additional intervention. Adding HCG to a short cycle introduces a second variable that complicates attribution without a clear benefit.

For a 12-week Ostarine protocol, HCG at 500 IU subcutaneous every other day during the final three to four weeks of the cycle is a defensible optional addition. The rationale is specifically to reduce the depth of testicular desensitization heading into PCT, not to counteract SARMs-mediated suppression directly. Researchers choosing to include it should document it as a distinct protocol element and account for it when interpreting post-cycle LH and testosterone recovery.

HCG should not be run as a replacement for PCT, nor continued into the PCT window. Its role is to maintain testicular responsiveness so that the PCT compound has functional tissue to signal to.

Post-cycle therapy: non-negotiable

The consensus across preclinical literature and documented beginner protocols is that any SARMs cycle producing measurable suppression requires a structured post-cycle therapy phase. PCT for a beginner protocol is narrow in scope: one selective estrogen receptor modulator (SERM), at a conservative dose, for a fixed duration, beginning the day after the final cycle dose.

The standard beginner PCT is tamoxifen (Nolvadex) at 20 mg once daily for four weeks. Tamoxifen blocks estrogen feedback at the hypothalamus and pituitary, which restores GnRH pulsatility and drives recovery of endogenous LH, FSH, and testosterone production. It is preferred over clomifene for a first protocol because the side-effect profile is generally milder in reported data and the 20 mg dose is well below the range associated with visual disturbances reported at higher SERM doses.

A four-week duration is appropriate for both the 8-week RAD-140 and 12-week Ostarine protocols described above. Extending PCT beyond four weeks without blood work showing incomplete recovery is not indicated; extending it based on subjective markers alone risks its own disruption of the HPG axis.

Starting PCT immediately after the final cycle dose — rather than waiting for a washout period — is conventional for SARMs because the half-lives are short relative to testosterone esters, and delaying PCT allows suppression to deepen while the compound clears. The post-PCT blood draw, taken four weeks after the final tamoxifen dose, is the objective check on whether recovery is complete.

Bringing the full protocol together

A conservative first SARMs protocol, expressed end-to-end, looks like this:

• Weeks -1 to 0: Baseline blood work (HPG panel, lipid panel, liver enzymes, CBC, BMP).
• Weeks 1–8 or 1–12: Primary compound at the daily dose stated above, held consistent.
• Mid-cycle (week 4 or week 6): Repeat HPG panel, lipid panel, liver enzymes.
• Optional (weeks 9–12 of Ostarine protocol only): HCG 500 IU subcutaneous every other day.
• Day after final cycle dose: Begin tamoxifen 20 mg daily for four weeks.
• Four weeks after final PCT dose: Full repeat blood panel to confirm recovery.

The discipline in this framework is in what it excludes as much as in what it contains. A single compound, a fixed dose, a fixed duration, a documented PCT, and three blood draws. Adding compounds, extending duration, escalating dose mid-cycle, or substituting PCT with over-the-counter "natural" alternatives all move the protocol away from something characterizable toward something that cannot be evaluated.

Open questions

Several aspects of SARMs pharmacology remain under-characterized in a way that should inform how researchers interpret their own data. Long-term cardiovascular outcomes beyond the 12–16 week window of most published trials are not well established. The question of whether repeated cycles produce cumulative lipid or hepatic effects is open. The tissue-selectivity profile that defines the compound class appears to be dose-dependent, and the dose at which selectivity degrades has not been precisely mapped for most SARMs outside of Ostarine. Researchers running a first protocol should treat their own blood work as the primary signal and the published literature as a frame for interpretation, rather than as a substitute for individualized monitoring.